The COVID-19 epidemic (Coronavirus Disease 2019) currently raging in France is an emerging infectious disease linked to a virus of the genus coronavirus (SARS-CoV-2). Epidemiologically, acute myeloblastic leukemias (AML) are the most common of acute leukemias. The incidence of acute lymphoblastic leukemia (ALL) is 900 new cases in France in 2018, of which 57% in humans. The treatments administered to AML and ALL patients induce variable immunosuppression: neutropenia, neuropathy, deficits in humoral or cellular immunity or combinations of these deficits. Patients with AML or ALL therefore represent a population at high risk of developing a serious form in the event of infection with SARS-CoV-2. To date, no data is available in the literature to assess the impact of the COVID-19 epidemic in the population of patients with acute leukemia. The main objective of the study is to determine the clinical and biological prognostic factors during SARS-CoV-2 infection in patients with acute leukemia.
Study Type
OBSERVATIONAL
Enrollment
79
Chu Amiens
Amiens, France
CHU ANGERS - Maladies du sang
Angers, France
Ch Avignon
Avignon, France
CH de la Côte Basque - Hématologie
Bayonne, France
CHU Caen - IHBN - Hématologie Clinique
Caen, France
Centre Hospitalier Sud Francilien
Corbeil-Essonnes, France
Centre Hospitalier de Dunkerque
Dunkirk, France
CHU de Grenoble - Hopital Michallon
Grenoble, France
Centre Hospitalier du Mans
Le Mans, France
Hôpital Saint Vicent de Paul
Lille, France
...and 17 more locations
Clinical prognostic factors for infection with COVID-19
Factors associated with overall survival will be analyzed : center, sex, leukemia subtype, previous treatment by corticosteroids, and comorbidities (respiratory, renal, cardiac, weight, diabetes)
Time frame: Day 0
Biological prognostic factors for infection with COVID-19
neutrophils and lymphocytes count at the time of SARS-COV2 infection
Time frame: Day 0
Medical care of Coronavirus infection
Describe the management carried out concerning coronavirus infection and its impact of the treatment of acute leukemia (non-invasive ventilation, orotracheal intubation, vasopressor requiring, treatments used, cause of death
Time frame: within 12 months after diagnosis
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.